MNKD · Mannkind Corp
$3.82
+0.02 (+0.53%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.07B
Shares
321.54M
Volume · Oct 5
2.63M
Avg daily vol (3M)
4.52M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.80
Open$4.01
Day$3.71–4.01
52W close$2.28–6.21
Avg vol 30d4.4M
Short int29.4M · 9.1% float · 9.1d
Short vol57%
Last earningsAug 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 4 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$393.63M
Trailing 12 months
Net income (TTM)
−$43.61M
Trailing 12 months
Revenue growth YoY
+42.9%
Year over year
Operating margin
2.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.7%
Year over year · fewer shares
Price change (1Y)
-30.8%
Trailing year
Short interest
9.1%
Latest settlement · 9.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. MannKind delivered all three 2026 catalysts: Afrezza pediatric approval and launch, Furoscix ReadyFlow FDA approval with late-August availability, and positive nintedanib DPI Phase 1b data enabling Phase 2 advancement. Q2 revenue rose 43% YoY to $109.4M but GAAP net loss widened to $19M as planned investments in launches and the MNKD-201 program ramped.
Bullish
- + Delivered all three stated 2026 catalysts, including Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib DPI Phase 1b data.
- + Furoscix Q2 net sales were $22.2M, with IDN doses up 36% and nephrology units up 67% over Q1.
- + Afrezza pediatric launch is off to a strong early start, with 1 in 3 of the top 100 pediatric rapid-acting writers having prescribed.
- + Closed a $50M PIPE, giving pro forma cash of $161M to fund the $45M CVR and support launches and MNKD-201 development.
Bearish
- − Q2 GAAP net loss was $19M vs. $0.7M net income in Q2 2025, driven primarily by planned investments in launches and the MNKD-201 program plus the larger post-scPharma cost base.
- − Afrezza Q2 net sales fell 7% YoY to $17.0M as adult resources were pulled back, and Q2 V-Go sales fell 33% YoY.
- − Gross margin percentage decreased YoY due to inclusion of the lower-margin Furoscix product.
- − R&D expense rose 32% YoY to $18.0M and SG&A rose 84% YoY to $58.3M as the company funds two launches and pipeline development.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−2%
below
RSI (14)
53
neutral
MACD trend
Positive
52-week position
39%
mid-range
Momentum
relative strength
1-month return
−4%
trailing
6-month return
+44%
trailing
YTD return
−33%
this year
Relative strength
+32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
1 of 261 funds reported for Sep 30 · net +1.1K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.14% of float · ▲ +10.7% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
261 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+22%
Y/Y
EPS growth
−80%
Y/Y
Free cash flow
$13.7M
Balance sheet
$89.0M
net debt
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
full-year 2026
FURO6 revenue
Initiated
$110M – $120M
this year
FURO6 sales
$110M – $120M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
−2%
Neutral
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
39%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
1 of 261 funds reported for Sep 30 · net +1.1K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.14% of float · ▲ +10.7% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
261 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $4 · 39%
Range high $6
vs 200-day avg -5%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MNKD
this stock
Mannkind Corp
|
$1.07B | -33.0% | +22.2% | — | 9.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MNKD | +13.8% | -4.0% | +43.9% | -2.6% | -33.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +14.0% | -3.6% | +31.8% | -3.5% | -45.8% |